This month marks the 10,000th screening for a study supported by our Clinical Trials Accelerator Platform (CTAP). Find out what a study screening is and what this means for CF research below - or read more about our wider impact in our 2026 CTAP impact report.
Infections caused by the Burkholderia cepacia complex (BCC) group of bacteria cause dangerous lung infections for people with CF and they’re very difficult to treat. In this Early Career Researcher Development Award, University of Leicester-based Dr Jessica Lewis is advancing research into an alternative treatment to antibiotics known as phage therapy.
The study is looking to find new, reliable and straightforward ways of testing for infections that do not require sputum. Accurate diagnosis of infections is more difficult as improved health, in particular with CFTR modulators, leads to less sputum being coughed up. This study will look at new ways of testing for infections that are acceptable for people with CF or chronic suppurative lung disease (CSLD) in order to detect, monitor and treat lung infections early. People with CSLD often suffer with similar infections to people with CF, and so are being invited to take part in the study to...
The Tracker study is a mostly home-based study to understand the causes of exacerbations in people with cystic fibrosis (CF). We will recruit people with CF when they are well and they will track their symptoms, lung function and viral infections by sending back samples from home. These samples and information will help us build up a detailed picture of what makes one person more likely to have an exacerbation rather than recover, and also what the triggers are that make this more likely. For example, we are looking in detail at viral infections, as well as sputum bacterial infections...
Trials Tracker ID
TT014530
Age range
16 years and older
Length of participation
12 months (6 months of active sampling, and date review at 12 months)
Organ Donation Week is a chance to reflect on the importance of organ donation and donors.
To mark the week, we’re pleased to share the UK CF Medical Association (CFMA) and Association of Lung Transplant Physicians (ALTP) care recommendations for people with cystic fibrosis following a lung transplant, developed with involvement from people with CF who have had a transplant.
Cystic Fibrosis Trust is committed to funding research that is equitable, inclusive, and representative of the entire cystic fibrosis (CF) community, including consideration of sex and gender in biomedical research. Embedding EDI into your research design strengthens scientific rigour, enhances generalisability, and ensures research outcomes benefit everyone living with CF. EDI considerations form part of the assessment criteria and will be evaluated by scientific and lived experience reviewers, within our Research Grants Review Committee.
